Smithwood Advisers’s Allergan plc AGN Stock Holding History

Smithwood Advisers’s Portfolio AGN Stock Details AGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-125,000	Closed	-$33.5M	–	14
2016 Q1	$33.5M	Buy	+125,000	New	+$35.8M	10.86%	4

Other funds holding AGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Smithwood Advisers's AGN Position: Q2 2016 in Review

Smithwood Advisers sold out of Allergan plc (AGN) in Q2 2016, closing a stake of 125,000 shares — an estimated $33.5M sold.

Smithwood Advisers first reported a position in AGN in Q1 2016 and held it in 1 quarter. The position peaked at $33.5M in Q1 2016. 1,107 funds tracked by Wall St. Rank hold AGN as of Q2 2016.

Smithwood Advisers reported no remaining Allergan plc position as of Q2 2016 after selling out during the quarter.
Smithwood Advisers sold 125,000 Allergan plc shares in Q2 2016, an estimated $33.5M.
Smithwood Advisers first reported a position in Allergan plc in Q1 2016 and held it in 1 quarter.
Smithwood Advisers's Allergan plc position peaked at $33.5M in Q1 2016.
1,107 funds tracked by Wall St. Rank held Allergan plc as of Q2 2016.

Based on Smithwood Advisers's 13F filing for Q2 2016, filed 15 Aug 2016.